In a single multiomic assay, the Illumina 5-base solution combines DNA methylation and genomic variant calling into one workflow, enabling deeper biological discoveries through a simple, integrated solution.








Illumina Protein Prep enables detection of low-concentration blood biomarkers previously only found in cerebrospinal fluid, this less invasive proteomic profiling has great potential for neurodegenerative disease studies.

Illumina Spatial Technology – AGBT Scientific Poster
Illumina spatial technology (coming 2026) will offer scalable, end-to-end analysis powered by DRAGEN, integrating cell-based binning and flexible data export, with user-friendly tools for image processing, visualization, and marker gene identification.
Emma Baple, Professor of Genomic Medicine, and Andrew Parrish, Clinical Bioinformatician, share insights on their research using Constellation Mapped Read Technology. Their work in rare disease genomics and sequencing pipelines highlights how this innovation could transform Rapid Genome Sequencing and improve healthcare equity across diverse populations.
In this episode of Mendelspod podcast, Theral Timpson speaks to Krishna Morampudi from Illumina, about the recent definitive agreement to acquire SomaLogic and the launch of Illumina Protein Prep, a new end-to-end, NGS-based, high-throughput proteomics research solution.
In a landmark study by Douglas Kirsher and colleagues at Alkahest, eight plasma proteomics platforms were benchmarked using 78 samples, identifying over 13,000 unique proteins. SomaScan® 11K offered the broadest coverage and highest precision, while MS-based methods revealed unique proteoform insights. These findings benchmark current technologies and provide a valuable resource for developing future diagnostics and therapeutics.
Learn more about Illumina Protein Prep

In this study, Villa-Vasquez et al. used a multiomics approach—including CRISPR gene editing, RNA-seq, proteomics, and imaging—to investigate AGBL5-linked retinitis pigmentosa. They showed that AGBL5 knockout leads to hyperglutamylation and defective ciliogenesis in retinal cells. Rescue was achieved via AGBL5 overexpression or TTLL5 knockdown, revealing two therapeutic strategies. Insights from combined RNA and protein data highlight the role of AGBL5 in cilia regulation and retinal disease mechanisms.
Learn more about Multiomics tools from Illumina

Published by Breast Cancer Genetics experts in London, the authors deployed the 313-SNP polygenic risk score (PRS 313) using the iCOGS chip based on Illumina array technology to assess breast cancer risk after in situ disease. In this research study, it was shown that PRS 313 could identify women with Ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS) who are at higher risk of future breast cancer events. These findings suggest PRS 313 has promise to be applied in future personalized surveillance and treatment strategies for women with in situ breast cancer.
Learn more about Illumina Infinium OncoArray-500K BeadChip

Learn about the Illumina Single Cell Prep (ISCP) chemistry which significantly reduces cost and simplifies workflow, for any lab. The ebook highlights references for research studies showing ISCP in action, using up to 2000, up to 20K and up to 100,000 cells.